TT-00434

TT-00434 is an irreversible, highly selective small molecule inhibitor of fibroblast growth factor receptors FGFR1, FGFR2, and FGFR3. It has demonstrated potent preclinical antitumor activity against tumors harboring FGFR aberrations. The drug is being developed primarily for the treatment of neoplasms (cancers), urogenital diseases, and digestive system disorders. Indications under investigation include HR-positive/HER2-low solid tumors, stomach cancer, bladder cancer, and other advanced malignant solid neoplasms. In a first-in-human Phase 1 clinical trial in patients with advanced solid tumors who had exhausted standard treatments, TT-00434 was administered orally once daily in 28-day cycles. The study aimed to determine safety, pharmacokinetics/pharmacodynamics (PK/PD), recommended Phase 2 dose (RP2D), and preliminary antitumor activity. Early results showed manageable safety with common adverse events including hyperphosphatemia and fatigue; stable disease was observed in some patients with bladder or endometrial cancer; one patient with cholangiocarcinoma harboring an FGFR fusion achieved partial response[1][6][10].